Abstract:Background: Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated in clinical trials. Sensitive and dynamic response biomarkers are needed to assess the efficacy of such candidate therapies. Neurofilament light chain (NfL) is a biomarker of neurodegeneration that increases in cerebrospinal fluid (CSF) and blood with progression of HD. However, it remains unknown whether NfL in biofluids could serve as a response biomarker for assessing the efficacy of disease-modifying therapies for HD. Methods: Longitudinal plasma and cross-sectional CSF samples were collected from the YAC128 transgenic mouse model of HD and wild-type (WT) littermate control mice throughout the natural history of disease. Additionally, biofluids were collected from YAC128 mice following intracerebroventricular administration of an antisense oligonucleotide (ASO) targeting the mutant HTT transgene (HTT ASO), at ages both before and after the onset of disease phenotypes. NfL concentrations in plasma and CSF were quantified using ultrasensitive single-molecule array technology. Results: Plasma and CSF NfL concentrations were significantly elevated in YAC128 compared to WT littermate control mice from 9 months of age. Treatment of YAC128 mice with either 15 or 50 µg HTT ASO resulted in a dose-dependent, allele-selective reduction of mHTT throughout the brain at a 3-month interval, which was sustained with high-dose HTT ASO treatment for up to 6 months. Lowering of brain mHTT prior to the onset of regional brain atrophy and HD-like motor deficits in this model had minimal effect on plasma NfL at either dose, but led to a dose-dependent reduction of CSF NfL. In contrast, initiating mHTT lowering in the brain after the onset of neuropathological and behavioural phenotypes in YAC128 mice resulted in a dose-dependent stabilization of NfL increases in both plasma and CSF. Conclusions: Our data provide evidence that the response of NfL in biofluids is influenced by the magnitude of mHTT lowering in the brain and the timing of intervention, suggesting that NfL may serve as a promising exploratory response biomarker for HD.

Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease

Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light

Evaluation of Blood Glial Fibrillary Acidic Protein As a Potential Marker in Huntington's Disease

A 14-year longitudinal study of neurofilament light chain dynamics in premanifest and transitional Huntington's disease

Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3

A multicentre validation study of the diagnostic value of plasma neurofilament light

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson's disease

Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice

Serum Neurofilament Dynamics Predicts Cognitive Progression in De Novo Parkinson's Disease.

Investigation of serum neurofilament light chain as a biomarker in Fabry disease

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3

Serum Neurofilament Light Chain Levels May Be a Marker of Lower Motor Neuron Damage in Amyotrophic Lateral Sclerosis

Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease

Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value

Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real‐Time Treatment Response

Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly: A Longitudinal Study.

Neurofilament light chain as a biomarker in neurological disorders

Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management

Longitudinal Change in Brain Function and Structure Related to Plasma Neurofilament Light Protein in Early-Stage Parkinson’s Disease